By Mark Geanacopoulos, PhD; Ruth Barratt, PhD, DVM; CDER, Office of Translational Sciences
Since 2008, the Critical Path Initiative has supported FDA’s program of intramural research projects in regulatory science, with…
By Janet Woodcock, MD, Director, CDER, FDA; Anne M. Rowzee, PhD, Lead Writer/Editor, Division of Online Communications, FDA
Many developments have brought clinical trial data transparency to the forefront of our stakeholders’ minds – from the expanding...
By Judith Glennie, PharmD; President, J.L. Glennie Consulting, Inc., Canada
Outside of its regulatory responsibilities, the federal government’s role in the Canadian health system tends to be limited...
